Intersect ENT

Cardio Flow Announces Completion of First Commercial Cases of Innovative FreedomFlow Orbital Atherectomy Platform—and Appointment of Chief Operating Officer

Retrieved on: 
Monday, October 30, 2023

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231027207271/en/
    Cardio Flow announced the successful completion of its first commercial cases in leading medical centers across the U.S.
  • Michael Kallok, Ph.D., CEO of Cardio Flow, also announced the appointment of Scott Kraus as Chief Operating Officer.
  • Most recently, Scott served as Vice President of Sales & Marketing for Cardio Flow and was responsible for overseeing all commercial functions.
  • Most notably, he was part of the commercial team at CSI that launched the orbital atherectomy systems.

Patient Square Capital Announces Formation of Elevage Medical Technologies to Partner with Growth-Stage Medical Device Companies

Retrieved on: 
Monday, May 1, 2023

MENLO PARK, Calif., May 1, 2023 /PRNewswire/ -- Patient Square Capital ("Patient Square"), a leading health care investment firm, today announced the formation of Elevage Medical Technologies ("Elevage"), a new portfolio company to support the growth of promising medical device companies by providing capital and deep strategic expertise. Elevage will be led by newly appointed CEO Evan Melrose, M.D., who brings more than 25 years of experience in health care across clinical, investment, and operational roles.

Key Points: 
  • MENLO PARK, Calif., May 1, 2023 /PRNewswire/ -- Patient Square Capital ("Patient Square"), a leading health care investment firm, today announced the formation of Elevage Medical Technologies ("Elevage"), a new portfolio company to support the growth of promising medical device companies by providing capital and deep strategic expertise.
  • Patient Square has made a capital commitment of $300 million to Elevage Medical Technologies.
  • "Many medical technologies that have been in development for a decade or more are right at the cusp of making a major impact on patient lives," said Jim Momtazee, Managing Partner of Patient Square.
  • "This is an exciting time for innovation in the medical device field, and through Elevage Medical Technologies, we will support the growth of new, life-changing technologies to impact patient care," said Evan Melrose, M.D., CEO of Elevage Medical Technologies.

Global Drug-Eluting Stent Market Analysis Report 2023: A $119.6 Million Market by 2029 with Intersect ENT Dominating - ResearchAndMarkets.com

Retrieved on: 
Monday, April 10, 2023

The "Global Drug-Eluting Stent Market Size, Share, & COVID-19 Impact Analysis 2023-2029 - MedCore" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Drug-Eluting Stent Market Size, Share, & COVID-19 Impact Analysis 2023-2029 - MedCore" report has been added to ResearchAndMarkets.com's offering.
  • The comprehensive report on the market focuses solely on drug-eluting stents and does not include its extended set.
  • The company's monopoly on the market is a significant factor in the growth of the drug-eluting stent market.
  • The Global drug-eluting stent market was led by Intersect ENT.

U.S. Venture Partners Raises $400M Early-Stage Venture Capital Fund

Retrieved on: 
Wednesday, December 14, 2022

U.S. Venture Partners (USVP), a premier Silicon Valley venture capital firm, announced today the closing of USVP XIII, a $400M fund focused on Series A and B investments.

Key Points: 
  • U.S. Venture Partners (USVP), a premier Silicon Valley venture capital firm, announced today the closing of USVP XIII, a $400M fund focused on Series A and B investments.
  • The new fund continues USVPs successful early-stage investment franchise, building leading companies in cybersecurity, enterprise software, consumer and healthcare.
  • 2022 will mark the eleventh consecutive year in which USVP distributions to limited partners exceeded called capital.
  • U.S. Venture Partners (USVP) is a leading Silicon Valley venture capital firm, partnering with entrepreneurs to transform their ideas into world-changing companies.

ENT and Allergy Associates, LLP Wins NextGen 2022 Excellence in Healthcare Award for their Implementation of the RCxRules Revenue Cycle Engine

Retrieved on: 
Monday, November 21, 2022

WHITE PLAINS, N.Y., Nov. 21, 2022 /PRNewswire/ -- ENT and Allergy Associates, LLP (ENTA) the largest ear, nose, throat, allergy, and audiology practice in the country, was recognized by NextGen Healthcare with a 2022 Excellence in Healthcare award for their implementation of the RCxRules Revenue Cycle Engine .

Key Points: 
  • WHITE PLAINS, N.Y., Nov. 21, 2022 /PRNewswire/ -- ENT and Allergy Associates, LLP (ENTA) the largest ear, nose, throat, allergy, and audiology practice in the country, was recognized by NextGen Healthcare with a 2022 Excellence in Healthcare award for their implementation of the RCxRules Revenue Cycle Engine .
  • The selection was made at the annual NextGen User Group Meeting in Nashville, TN.
  • NextGen hosted 1,800 healthcare professionals from all specialties at this year's UGM.
  • Congratulations to Margaret Hargrove and the Revenue Cycle Management and Operations teams at ENTA for a successful rollout of the RCxRules Revenue Cycle Engine, which has helped them to improve their financial performance while streamlining their workflow.

SecuriThings Closes $21 Million to Automate the Management of Enterprise Physical Security Devices

Retrieved on: 
Thursday, October 13, 2022

TEL AVIV, Israel, Oct. 13, 2022 /PRNewswire/ -- SecuriThings today announced it has raised a $21 million Series B funding round led by U.S. Venture Partners (USVP) and participation from Swisscom Ventures, bringing the company's total amount raised to $39 million. Existing investors Aleph, Firstime VC and Cresson Management also participated in the round.

Key Points: 
  • SecuriThings is redefining the way organizations manage and secure physical security devices at scale, helping physical security teams ensure device performance while reducing costs.
  • The volume and complexity of managing all these devices is incredibly challenging," said Roy Dagan, CEO of SecuriThings.
  • We're thrilled to be on their growth journey as SecuriThings becomes the de facto platform for managing physical security operations across organizations worldwide."
  • Founded by leading security and IoT experts, SecuriThings empowers operations and IT professionals to automate the operational management of physical security devices, while also ensuring full compliance and security within their organization.

Morehouse School of Medicine's "Danforth Dialogues" Podcast Holds A Discussion With EMILY's List President Laphonza Butler

Retrieved on: 
Monday, August 8, 2022

ATLANTA, Aug. 8, 2022 /PRNewswire-PRWeb/ -- Morehouse School of Medicine (MSM) today published the latest edition of its new "Danforth Dialogues" podcast, featuring a "Conversation of Significance" between MSM President and CEO Dr. Valerie Montgomery Rice and EMILY's List President Laphonza Butler discussing the intersection of public health and public policy in this unprecedented period in the history of the United States.

Key Points: 
  • The podcast was recorded before a live audience of prominent African American female physicians and healthcare leaders at a luncheon hosted by Dr. Montgomery Rice.
  • Named after the
    historic Danforth Chapel on the Morehouse College campus, the podcast series features a cross-section of guests and topics.
  • Founded in 1975, Morehouse School of Medicine (MSM) is among the nation's leading educators of primary care physicians, biomedical scientists, and public health professionals.
  • Morehouse School of Medicine's faculty and alumni are noted for excellence in teaching, research, and public policy, as well as exceptional patient care.

Nalu Medical, Inc. Names Thomas West President and Chief Executive Officer

Retrieved on: 
Thursday, July 14, 2022

CARLSBAD, Calif., July 14, 2022 /PRNewswire-PRWeb/ -- Nalu Medical, Inc. ("Nalu"), a private company focused on innovative and minimally invasive solutions for chronic neuropathic pain, announced today that the Board of Directors has appointed Thomas "Tom" West as President and Chief Executive Officer.

Key Points: 
  • CARLSBAD, Calif., July 14, 2022 /PRNewswire-PRWeb/ -- Nalu Medical, Inc. ("Nalu"), a private company focused on innovative and minimally invasive solutions for chronic neuropathic pain, announced today that the Board of Directors has appointed Thomas "Tom" West as President and Chief Executive Officer.
  • Mr. West remarked, "I am very excited and honored to be leading Nalu.
  • Mr. Fender added, "I am proud of the Nalu team and what we have accomplished to date.
  • Nalu, micro-IPG and the Nalu logo are trademarks of Nalu Medical, Inc.

Owens & Minor Elects Rita Johnson-Mills and Terri Kline to Board of Directors

Retrieved on: 
Wednesday, June 1, 2022

Owens & Minor, Inc. (NYSE: OMI), a leading global healthcare solutions company, today announced that Rita Johnson-Mills and Terri Kline have been elected to its Board of Directors, effective June 1, 2022.

Key Points: 
  • Owens & Minor, Inc. (NYSE: OMI), a leading global healthcare solutions company, today announced that Rita Johnson-Mills and Terri Kline have been elected to its Board of Directors, effective June 1, 2022.
  • Previously, Kline served on the board of directors of Apria, Inc., which was acquired by Owens & Minor in March 2022, and Intersect ENT, which was acquired by Medtronic, Inc. in May 2022.
  • Rita and Terri are both veteran leaders with proven track records partnering with healthcare enterprises, making them invaluable advisors for Owens & Minor, said Edward A. Pesicka, President and Chief Executive Officer, Owens & Minor.
  • Operating continuously since 1882 from its headquarters in Richmond, Va., Owens & Minor is a 140-year-old company powered by more than 20,000 global teammates.

RAPT Therapeutics Expands Leadership Team with Multiple Key Hires

Retrieved on: 
Wednesday, May 4, 2022

Gwen is a strategic business leader with a wealth of experience in building dynamic teams and we are very excited to welcome her to the RAPT leadership team, said Brian Wong, M.D., Ph.D., President and CEO of RAPT.

Key Points: 
  • Gwen is a strategic business leader with a wealth of experience in building dynamic teams and we are very excited to welcome her to the RAPT leadership team, said Brian Wong, M.D., Ph.D., President and CEO of RAPT.
  • In addition to Gwen, we are excited to welcome Jim and Shari to key leadership roles in clinical operations and program management.
  • Ms. Carscadden added, Im very excited to join RAPT given its exciting programs in inflammatory diseases and oncology.
  • Jim brings over 25 years of clinical operations experience in multiple therapeutic areas, including oncology and immunology.